NCT02323113 2023-02-08
Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
Calithera Biosciences, Inc
Phase 1/2 Terminated
Calithera Biosciences, Inc
Calithera Biosciences, Inc
Calithera Biosciences, Inc
Calithera Biosciences, Inc